{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:51:32Z","timestamp":1790898692066,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T00:00:00Z","timestamp":1489449600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T00:00:00Z","timestamp":1489449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA97452"],"award-info":[{"award-number":["U01 CA97452"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 CA097452"],"award-info":[{"award-number":["UM1 CA097452"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Children's Oncology Group Foundation","award":["K12CA076931"],"award-info":[{"award-number":["K12CA076931"]}]},{"name":"Children's Oncology Group Foundation","award":["K08CA18441"],"award-info":[{"award-number":["K08CA18441"]}]},{"DOI":"10.13039\/100003287","name":"Rally Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia & Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cookies of Kids\u2019 Cancer Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1111\/bjh.14569","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T21:23:47Z","timestamp":1489526627000},"page":"467-474","source":"Crossref","is-referenced-by-count":39,"title":["A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114)"],"prefix":"10.1111","volume":"177","author":[{"given":"Susan R.","family":"Rheingold","sequence":"first","affiliation":[{"name":"Division of Oncology and Center for Childhood Cancer Research; Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania; Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Tasian","sequence":"additional","affiliation":[{"name":"Division of Oncology and Center for Childhood Cancer Research; Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania; Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Whitlock","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology; Hospital for Sick Children; Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[{"name":"Division of Oncology and Center for Childhood Cancer Research; Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania; Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Borowitz","sequence":"additional","affiliation":[{"name":"Department of Pathology; Sidney Kimmel Cancer Center and Johns Hopkins School of Medicine; Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Liu","sequence":"additional","affiliation":[{"name":"Children's Oncology Group Operations Center; Monrovia CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G.","family":"Minard","sequence":"additional","affiliation":[{"name":"Dan L. Duncan Institute for Clinical and Translational Research; Baylor College of Medicine; Houston TX USA"},{"name":"TX Texas Children's Cancer Center; Baylor College of Medicine; Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fox","sequence":"additional","affiliation":[{"name":"Division of Oncology and Center for Childhood Cancer Research; Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania; Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda J.","family":"Weigel","sequence":"additional","affiliation":[{"name":"University of Minnesota; Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Blaney","sequence":"additional","affiliation":[{"name":"Dan L. Duncan Institute for Clinical and Translational Research; Baylor College of Medicine; Houston TX USA"},{"name":"TX Texas Children's Cancer Center; Baylor College of Medicine; Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,14]]},"reference":[{"key":"10.1111\/bjh.14569-BIB0001|bjh14569-cit-0001","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/pbc.24874","article-title":"Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study","volume":"61","author":"Bagatell","year":"2014","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1111\/bjh.14569-BIB0002|bjh14569-cit-0002","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nature Reviews Cancer"},{"key":"10.1111\/bjh.14569-BIB0003|bjh14569-cit-0003","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3324\/haematol.2009.010785","article-title":"Autocrine IGF-1\/IGF-1R signaling is responsible for constitutive PI3K\/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody","volume":"95","author":"Chapuis","year":"2010","journal-title":"Haematologica"},{"key":"10.1111\/bjh.14569-BIB0004|bjh14569-cit-0004","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1046\/j.1365-2141.1998.00776.x","article-title":"Relapsed lymphoblastic leukaemia in children: a continuing challenge","volume":"102","author":"Chessells","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1111\/bjh.14569-BIB0005|bjh14569-cit-0005","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1182\/blood-2008-02-137752","article-title":"Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia","volume":"113","author":"Crazzolara","year":"2009","journal-title":"Blood"},{"key":"10.1111\/bjh.14569-BIB0006|bjh14569-cit-0006","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-14-2888","article-title":"A phase I\/II study of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"21","author":"Daver","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/bjh.14569-BIB0007|bjh14569-cit-0007","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/(SICI)1097-0142(19980401)82:7<1387::AID-CNCR24>3.0.CO;2-1","article-title":"Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse - the Children's Cancer Group Experience","volume":"82","author":"Gaynon","year":"1998","journal-title":"Cancer"},{"key":"10.1111\/bjh.14569-BIB0008|bjh14569-cit-0008","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/2159-8290.CD-13-0929","article-title":"A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity","volume":"4","author":"Grabiner","year":"2014","journal-title":"Cancer Discovery"},{"key":"10.1111\/bjh.14569-BIB0009|bjh14569-cit-0009","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","article-title":"High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia","volume":"114","author":"Gutierrez","year":"2009","journal-title":"Blood"},{"key":"10.1111\/bjh.14569-BIB0010|bjh14569-cit-0010","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/pbc.22414","article-title":"Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference","volume":"54","author":"Horton","year":"2010","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1111\/bjh.14569-BIB0011|bjh14569-cit-0011","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/pbc.21296","article-title":"Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program","volume":"50","author":"Houghton","year":"2008","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1111\/bjh.14569-BIB0012|bjh14569-cit-0012","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/bjh.14569-BIB0013|bjh14569-cit-0013","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/pbc.25575","article-title":"A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children's Oncology Group phase 1 consortium study (ADVL1011)","volume":"62","author":"Loh","year":"2015","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1111\/bjh.14569-BIB0014|bjh14569-cit-0014","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","article-title":"Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study","volume":"120","author":"Messinger","year":"2012","journal-title":"Blood"},{"key":"10.1111\/bjh.14569-BIB0015|bjh14569-cit-0015","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"10.1111\/bjh.14569-BIB0016|bjh14569-cit-0016","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/bjh.14569-BIB0017|bjh14569-cit-0017","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3765.3765","article-title":"Phase I trial of the mTOR inhibitor everolimus given in combination with multiagent chemotherapy in relapsed childhood acute lymphoblastic leukemia","volume":"126","author":"Place","year":"2015","journal-title":"Blood"},{"key":"10.1111\/bjh.14569-BIB0018|bjh14569-cit-0018","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1182\/blood-2013-10-534297","article-title":"The addition of sirolimus to tacrolimus\/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group\/Pediatric Blood and Marrow Transplant Consortium trial","volume":"123","author":"Pulsipher","year":"2014","journal-title":"Blood"},{"key":"10.1111\/bjh.14569-BIB0019|bjh14569-cit-0019","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group Study [corrected]","volume":"26","author":"Raetz","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.14569-BIB0020|bjh14569-cit-0020","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1097\/MPH.0b013e318290c3d6","article-title":"Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Munster) study group","volume":"35","author":"Reismuller","year":"2013","journal-title":"Journal of Pediatric Hematology\/oncology"},{"key":"10.1111\/bjh.14569-BIB0021|bjh14569-cit-0021","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","article-title":"Shortening the timeline of pediatric phase I trials: the rolling six design","volume":"26","author":"Skolnik","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.14569-BIB0022|bjh14569-cit-0022","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1517\/13543784.15.10.1201","article-title":"Investigating mammalian target of rapamycin inhibitors for their anticancer properties","volume":"15","author":"Smolewski","year":"2006","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1111\/bjh.14569-BIB0023|bjh14569-cit-0023","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1200\/JCO.2010.33.4649","article-title":"Phase I study of temsirolimus in pediatric patients with recurrent\/refractory solid tumors","volume":"29","author":"Spunt","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.14569-BIB0024|bjh14569-cit-0024","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3647.3647","article-title":"The UK ALLR3 chemotherapy regimen for relapsed\/refractory acute lymphoblastic leukemia of childhood: a multi-institutional retrospective study of treatment related adverse events","volume":"124","author":"Sun","year":"2014","journal-title":"Blood"},{"key":"10.1111\/bjh.14569-BIB0025|bjh14569-cit-0025","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fonc.2014.00108","article-title":"Targeting the PI3K\/mTOR pathway in pediatric hematologic malignancies","volume":"4","author":"Tasian","year":"2014","journal-title":"Frontiers in Oncology"},{"key":"10.1111\/bjh.14569-BIB0026|bjh14569-cit-0026","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","article-title":"Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"129","author":"Tasian","year":"2016","journal-title":"Blood"},{"key":"10.1111\/bjh.14569-BIB0027|bjh14569-cit-0027","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1182\/blood-2005-05-1935","article-title":"The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL","volume":"107","author":"Teachey","year":"2006","journal-title":"Blood"},{"key":"10.1111\/bjh.14569-BIB0028|bjh14569-cit-0028","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2008-02-137141","article-title":"mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia","volume":"112","author":"Teachey","year":"2008","journal-title":"Blood"},{"key":"10.1111\/bjh.14569-BIB0029|bjh14569-cit-0029","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cll.2007.05.001","article-title":"Modern flow cytometry: a practical approach","volume":"27","author":"Tung","year":"2007","journal-title":"Clinics in Laboratory Medicine"},{"key":"10.1111\/bjh.14569-BIB0030|bjh14569-cit-0030","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","article-title":"Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance","volume":"10","author":"Wei","year":"2006","journal-title":"Cancer Cell"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14569","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjh.14569\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T07:49:13Z","timestamp":1625384953000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,14]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"URL":"https:\/\/doi.org\/10.1111\/bjh.14569","archive":["Portico"],"relation":{},"ISSN":["0007-1048"],"issn-type":[{"value":"0007-1048","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3,14]]}}}